About

Regulatory Due Diligence

Camneteq can perform Regulatory Due Diligence (RDD) for investors in the medical device sector by systematically evaluating a target company’s regulatory, quality, and compliance posture against global requirements (ISO 13485, MDSAP, FDA, EU MDR, etc.). The goal is to identify risks, valuation impacts, and post-acquisition priorities.
Below is a structured description of how Camneteq would deliver this service.

1.

Due Diligence Framework Overview

Camneteq would apply a multi-layered due diligence framework covering:

  • Regulatory compliance status
  • Quality Management System (QMS) maturity
  • Market access and approvals
  • Product lifecycle control
  • Post-market surveillance and risk exposure

This framework is aligned with:

  • ISO 13485:2016
  • MDSAP Audit Model
  • Regional requirements (FDA, EU MDR/IVDR, etc.)

2.

Regulatory Landscape & Market Access Review

Camneteq evaluates whether the target company has legal and sustainable market access.

Key Activities:

  • Review of product registrations and approvals:
    • CE marking (EU MDR compliance status)
    • FDA clearance/approval (510(k), PMA, De Novo)
    • Regulatory product clearance in other jurisdictions
    • MDSAP certification (if applicable)
  • Identification of:
    • Expired, missing, or conditional approvals
    • Transition risks (e.g., MDR legacy device issues)

Investor Value:

  • Confirms whether products can continue to be sold
  • Identifies risks that could disrupt revenue streams

3.

Quality Management System (QMS) Assessment

Camneteq assesses the maturity and robustness of the QMS against:

  • ISO 13485 requirements
  • MDSAP audit expectations

Focus Areas:

  • Document control and record management
  • CAPA (Corrective and Preventive Actions)
  • Internal audit effectiveness
  • Management review processes
  • Training and competency records

Typical Outputs:

  • QMS maturity score
  • Gap assessment vs. ISO 13485/MDSAP
  • Identification of systemic compliance weaknesses

Investor Value:

  • Highlights operational risks
  • Estimates remediation effort and cost

4.

Product Design & Technical Documentation Review

Camneteq performs a deep dive into design control compliance.

Evaluation Includes:

  • Design History File/Design and Development File (DHF)
  • Risk management files (ISO 14971 alignment)
  • Verification & validation evidence
  • Clinical evaluation (especially under EU MDR)

Red Flags:

  • Incomplete design controls
  • Weak clinical evidence
  • Poor traceability between requirements and testing

Investor Value:

  • Assesses sustainability of product approvals
  • Identifies risk of regulatory rejection or recall

5.

Manufacturing & Supply Chain Compliance

Camneteq evaluates production and supplier control processes.

Key Elements:

  • Process validation status
  • Supplier qualification and monitoring
  • Incoming inspection controls
  • Traceability systems (UDI, batch/serial tracking)

MDSAP Lens:

  • Purchasing controls (critical audit area)
  • Production and service controls

Investor Value:

  • Reveals risks in scalability and quality consistency
  • Identifies potential supply chain vulnerabilities

6.

Post-Market Surveillance & Vigilance Review

Camneteq assesses how the company handles real-world product performance and safety.

Areas Reviewed:

  • Complaint handling processes
  • Adverse event reporting (FDA MDR, EU vigilance)
  • PMS and PMCF systems (EU MDR)
  • Recall history and field safety actions

Red Flags:

  • Underreported events
  • Delayed reporting NC/ CAPA/ Vigilance
  • Weak trending and signal detection

Investor Value:

  • Identifies hidden liability risks
  • Evaluates reputational and regulatory exposure

7.

Audit & Inspection History

Camneteq reviews past interactions with regulators and notified bodies.

Includes:

  • FDA inspection outcomes (483s, warning letters)
  • Notified Body audit reports
  • MDSAP audit findings

Analysis:

  • Recurring nonconformities
  • Severity of findings (minor vs. major)
  • Effectiveness of CAPA responses

Investor Value:

  • Indicates likelihood of future enforcement actions
  • Provides insight into compliance culture

8.

Regulatory Pipeline & Change Impact

Camneteq evaluates future regulatory risks and readiness.

Focus:

  • MDR/IVDR transition plans
  • Upcoming product submissions
  • Impact of regulatory changes (e.g., new FDA QMSR)

Investor Value:

  • Determines future investment requirements
  • Identifies potential revenue delays or barriers

9.

Risk Scoring & Investment Impact Analysis

Camneteq translates findings into investor-relevant insights.

Deliverables:

  • Risk heatmap (low/medium/high)
  • Financial impact estimation:
    • Cost of remediation
    • Risk of lost revenue
  • Timeline to compliance

Example Categories:

  • Critical: Market access at risk
  • Major: Significant remediation needed
  • Minor: Process improvements required

10.

Actionable Remediation Roadmap

Beyond identifying issues, Camneteq provides:

  • Prioritized remediation plan
  • Estimated:
    • Cost
    • Resources
    • Timeline
  • Quick wins vs. long-term fixes

Investor Value:

  • Enables informed valuation adjustments
  • Supports post-acquisition integration planning

11.

Reporting & Executive-Level Insights

Camneteq would deliver:

Detailed Report:

  • Full regulatory and QMS assessment
  • Evidence-based findings

Executive Summary:

  • Key risks
  • Investment implications
  • Go / No-Go considerations

Optional:

  • Board-level presentation
  • Q&A support during deal evaluation

12.

Differentiation of Camneteq Approach

Camneteq’s value lies in:

  • Audit-ready methodology (MDSAP-aligned)
  • Combination of regulatory + operational insight
  • Focus on investor decision-making (not just compliance)
  • Ability to support post-deal execution

Example Due Diligence Workflow

Phase 1 – Planning

  • Define scope (products, markets, sites)
  • Document request list

Phase 2 – Review

  • Desktop assessment of QMS and technical files
  • Stakeholder interviews

Phase 3 – On-site / Virtual Audit

  • Deep-dive into critical processes
  • Evidence verification

Phase 4 – Analysis

  • Risk scoring
  • Gap identification

Phase 5 – Reporting

  • Final report + executive briefing

Summary

Camneteq performs Regulatory Due Diligence by:

  • Verifying market access legitimacy
  • Assessing QMS maturity against ISO 13485 and MDSAP
  • Evaluating product compliance and technical documentation
  • Identifying hidden regulatory and quality risks
  • Translating findings into financial and strategic investment insights